



**NEW MEDICINE APPLICATIONS BROUGHT TO THE  
BORDERS FORMULARY COMMITTEE (BFC)  
AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC)  
2021/2022**

**New Medicine Product/Device Endorsement Categories**

<b>A</b>	Approved for general use - hospital and general practice
<b>B</b>	Approved for specialist use only
<b>C</b>	Approved for specialist initiation, with ongoing prescribing in general practice
<b>D</b>	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)
<b>E</b>	Not approved (reason given to applicant)
<b>F</b>	No decision – further information required (listed here)

<b>Green</b>	<b>Unrestricted General Use</b> Used widely and in accordance with a respectable, responsible body of clinical opinion (e.g. BNF for children; SIGN/NICE recommendation; royal college guidelines)
<b>Amber</b>	<b>General Use With Restrictions (Prescribers to be outlined)</b> Supporting clinical evidence has been evaluated by NHS Borders ADTC/Formulary committee. Local use has peer group support and reflects practice in other NHS Board areas. May require “shared care protocol”. (include information here) Specific patient consent not normally required.
<b>Red</b>	<b>Specialist Use Only</b> Supporting clinical evidence has been evaluated by NHS Borders ADTC/Formulary committee. Limited evidence of efficacy available. Rarely used or may have serious potential side effects requiring close supervision of treatment Specific patient consent indicated.
<b>Black</b>	Not Approved for use

**NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 28<sup>th</sup> APRIL 2021**

NMA	Indication	Speciality	BFC Decision
Dapagliflozin (Forxiga)	Treatment of symptomatic chronic heart failure with reduced ejection fraction	Cardiology	Approved Category B
Pentosan polysulfate sodium (Elmiron)	Bladder pain syndrome	Urology	Approved Category B
Certolizumab pegol (Cimzia)	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy	Dermatology	Approved Category B

**NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 26<sup>th</sup> MAY 2021**

NMA	Indication	Speciality	ADTC Decision
No applications			

**NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 23<sup>rd</sup> JUNE 2021**

NMA	Indication	Speciality	BFC Decision
Naloxone (Nyxoid)	Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings	BAS	Approved Category A
Sodium zirconium cyclosilicate (Lokelma)	Treatment of hyperkalaemia in adult patients, with SMC restriction	Diabetes	Approved Category B

**NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 28<sup>th</sup> JULY 2021**

NMA	Indication	Speciality	ADTC Decision
No applications			

**NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 25<sup>th</sup> AUGUST 2021**

NMA	Indication	Speciality	BFC Decision
Baricitinib (Olumiant)	Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.	Dermatology	Category B
Paraffin-Free Ointment (Epimax)	Paraffin-free emollient for intensive rehydration of dry skin conditions such as psoriasis and eczema. Can be used as a moisturiser, bath additive, soap substitute or in wet wrap techniques.	Dermatology	Category A
Guselkumab (Tremfya)	Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis in adult patients who have had an	Rheumatology	Category E (resubmit with

	inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.		additional information requested)
--	--	--	-----------------------------------

### NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 22<sup>nd</sup> SEPTEMBER 2021

NMA	Indication	Speciality	ADTC Decision
Sarilumab (Kevzara)	Treatment of adult patient admitted to ICU / high dependency with COVID19 pneumonia.	ICU	Category B

### NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 27<sup>th</sup> OCTOBER 2021

NMA	Indication	Speciality	BFC Decision
Guselkumab (Tremfya)	Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.	Rheumatology	Category B
Casirivimab+Imdevimab (Ronapreve)	Use in treatment of Covid19	ITU	Category B
Fremanezumab (Ajovy)	For prophylaxis of migraine in adults who have at least four	Neurology	Category B

	migraines per month. SMC restriction for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventative treatments.		
--	---	--	--

**NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 24<sup>th</sup> NOVEMBER 2021**

NMA	Indication	Speciality	ADTC Decision
None			

**From November 2021 - NEW MEDICINE APPLICATIONS will be discussed at EAST REGIONAL FORMULARY COMMITTEE not by Borders Formulary Committee.**

**NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 26<sup>th</sup> JANUARY 2022**

NMA	Indication	Speciality	ADTC Decision
Coloplast (Brava Protective Seal – code 12035 and 12045)	For use around a stoma to build up area, absorb excess moisture, provide comfort, prevent bag leaks, prevent skin breakdown and in turn reduce the amount of bag changes required.	Stoma Service	Category C
Sarilumab (Kevzara)	Rheumatoid Arthritis.	Rheumatology	Category B

**NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 23<sup>rd</sup> MARCH 2022**

NMA	Indication	Speciality	ADTC Decision
None			